Evidence map›Paper›PMID 33967764›Full record

ArticleFrontiers in pharmacology2021

Corrigendum: Metabolic Profiling of a CB2 Agonist, AM9338, Using LC-MS and Microcoil-NMR: Identification of a Novel Dihydroxy Adamantyl Metabolite.

Chandrashekhar Honrao, Xiaoyu Ma, Shashank Kulkarni, Vinit Joshi, Michael Malamas, Alexander Zvonok, JodiAnne Wood, Roger A Kautz, David Strand, Jason J Guo and 1 more

Open access · goldAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Chandrashekhar HonraoCenter for Drug Discovery and Department of Pharmaceutical Sciences, Northeastern University, Boston, MA, United States.
Xiaoyu MaCenter for Drug Discovery and Department of Pharmaceutical Sciences, Northeastern University, Boston, MA, United States.
Shashank KulkarniCenter for Drug Discovery and Department of Pharmaceutical Sciences, Northeastern University, Boston, MA, United States.
Vinit JoshiCenter for Drug Discovery and Department of Pharmaceutical Sciences, Northeastern University, Boston, MA, United States.
Michael MalamasCenter for Drug Discovery and Department of Pharmaceutical Sciences, Northeastern University, Boston, MA, United States.
Alexander ZvonokMAK Scientific LLC, Burlington, MA, United States.
JodiAnne WoodCenter for Drug Discovery and Department of Pharmaceutical Sciences, Northeastern University, Boston, MA, United States.
Roger A KautzBarnett Institute for Chemical and Biological Analysis, Northeastern University, Boston, MA, United States.
David StrandProtasis Corporation, Seabrook, NH, United States.
Jason J GuoCenter for Drug Discovery and Department of Pharmaceutical Sciences, Northeastern University, Boston, MA, United States.
Alexandros MakriyannisCenter for Drug Discovery and Department of Pharmaceutical Sciences, Northeastern University, Boston, MA, United States.
Northeastern University · USMAKScientific (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fphar.2020.575691.].

Indexed as

Adamantyl metabolismcannabinoid metabolismCB2 agonistCYP3A4 metabolismdi-hydroxyl adamantyl metaboliteLC-MSmetabolite identificationmicro-coil NMR

Identifiers

PMID33967764
PMCPMC8100890
OpenAlexW3089479515

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.